Open-house rebate agreement for epinephrine nasal spray
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Epinephrin (ATC-Code nach WHO: C01CA24) in der Darreichung Nasenspray
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The first submission deadline is fixed, and further deadlines are only available in a portal attachment not provided he...
Key participation documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') are referen...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Sep 2026
- Conclusion of non-exclusive rebate agreements for pharmaceutical products containing epinephrine in nasal spray form.
- Open-House participation model with no individual negotiations and no exclusivity.
Show full summary
This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements for epinephrine nasal spray (ATC C01CA24) in Germany. The contract is open to all interested pharmaceutical companies that meet and accept the stated participation conditions. No minimum purchase volume is guaranteed, no individual negotiations are conducted, and exclusivity is explicitly excluded. Participation documents must be obtained via DTVP after access approval, and submission is electronic via the portal communication function, not via the bidder tool. The notice is structured as a single lot, but the value is not stated.
Risks
The first submission deadline is fixed, and further deadlines are only available in a portal attachment not provided he...
Key participation documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') are referen...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Applicant must be a pharmaceutical company within the meaning of Section 4(18) AMG for the offered medicinal product.
Eligibility
- The bidder must submit the completed declaration on the absence of exclusion grounds with the participation documents.
Administrative
- The bidder must submit the declaration on Russia sanctions compliance using the specified form.
Buyer
Location
Erfurt, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Open-house rebate agreement for epinephrine nasal spray
Single lot covering the conclusion of non-exclusive pharmaceutical rebate agreements under Section 130a(8) SGB V for epinephrine (WHO ATC C01CA24) in nasal spray form. The lot is an Open-House model, so any interested pharmaceutical company may participate if it meets and accepts the participation conditions. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volume are stated. Performance/place of performance is Germany, with Dresden and the federal states of Saxony and Thuringia mentioned in the notice text.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Epinephrin (ATC-Code nach WHO: C01CA24) in der Darreichung Nasenspray
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 31 Jul 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 504345-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The first submission deadline is fixed, and further deadlines are only available in a portal attachment not provided he...
Key participation documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') are referen...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications